JPH04502256A - キメラdna―rna触媒活性配列 - Google Patents
キメラdna―rna触媒活性配列Info
- Publication number
- JPH04502256A JPH04502256A JP2508840A JP50884090A JPH04502256A JP H04502256 A JPH04502256 A JP H04502256A JP 2508840 A JP2508840 A JP 2508840A JP 50884090 A JP50884090 A JP 50884090A JP H04502256 A JPH04502256 A JP H04502256A
- Authority
- JP
- Japan
- Prior art keywords
- base sequence
- rna
- catalytically active
- dna
- hiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B64—AIRCRAFT; AVIATION; COSMONAUTICS
- B64D—EQUIPMENT FOR FITTING IN OR TO AIRCRAFT; FLIGHT SUITS; PARACHUTES; ARRANGEMENT OR MOUNTING OF POWER PLANTS OR PROPULSION TRANSMISSIONS IN AIRCRAFT
- B64D13/00—Arrangements or adaptations of air-treatment apparatus for aircraft crew or passengers, or freight space
- B64D13/06—Arrangements or adaptations of air-treatment apparatus for aircraft crew or passengers, or freight space the air being conditioned
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Aviation & Aerospace Engineering (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
(57)【要約】本公報は電子出願前の出願データであるため要約のデータは記録されません。
Description
【発明の詳細な説明】
キメラDNA−RNA触媒活性配列
発明の分野
本発明はDNA−RNA触媒活性分子に関する。特に本発明は例えばHIV−1
のRNA塩基配列を切断するのに効果的なキメラDNA−RNA−DNA−RN
A−DNA触媒活性分子に関する。
背景技術
リボザイムは多くのRNA自己消化反応に介在する構造RNA分子である。違っ
た二次構造をもつ2つの異なるトランス作用性リボザイム、”/%ンマーヘッド
”および”ヘアビグが明らかにされている。オンコジーンアンドエイズ(199
0)[引用コは次のように述べている:”他に可能な人工的なアプローチはりボ
ヌクレオチドの触媒活性中心およびデオキシヌクレオチドの周辺配列を含んだキ
メラ分子の開発である。RNA触媒活性中心およびDNA周辺配列からなるキメ
ラ触媒は著しい安定性を持ちながら生物学的活性を保持していることもまた想像
される。′ぺo −(Perreault)ら、 Nature、 344:
565−567 (1990)は、触媒活性を持ったある種のデオキシリボヌク
レオチドとりボオリゴヌクレオチドとの混合物を記載している。実際に治療に有
用なRNA−DNA触媒活性分子はまだ見つかってLlない。
発明の要約
本発明はRNA塩基配列を切断するのに有効なキメラDNA/RNA触媒活性分
子を提供する。本発明は特にHIV−1のRNA塩基配列を標的にして切断する
2つの異なったキメラDNA−RNA−DNA−RNA−DNA活性触媒分子を
提供する。これらのキメラ分子はRNA触媒活性中心の周辺のDNA塩基配列を
含む。HIV−117)基質RNAとの相互作用+tHIV−1,17)RNA
とDNA周スホスホジエステル結合断する。
発明の詳細な説明
一般的には本発明の触媒活性分子はハンマーヘッドあるいはヘアピンリボザイム
として機能する。好ましい分子は2つの知られているRNA触媒活性中心がそれ
ぞれの3゛および5゛末端においてDNA塩基配列を両側に配し、該DNAの対
応する5°および3゛末端と結合している構造からなる。従ってこれらの分子は
式IおよびIIにより表される:
1、 3’ X−AAAG−Y−AGUAGUC−Z 5’あるいは
Il、 3’ X−CAAAG−Y−AGUAGUC−Z 5’(式中、X、Y
およびZはDNA塩基配列部分であり、AAAG、CAAAGおよびAGUAG
UCは触媒RNA塩基配列部分である。)周辺のXおよびZの各塩基配列部分は
基質の切断部位の付近の適当な位置において基質RNAとの間に塩基間の相補結
合を起こしうるちのであればどのようなりNA塩基配列でもよい。これらの周辺
配列はホスホジエステル、ホスホロチオエート、メチルホスホネート、メチルホ
スフェートあるいは類似の成分であってよい。
Yは好ましくは式III:
5’ C−G 3゜
−T
−C
−C
G
T
で示される塩基間の相補対にみられるように、RNA塩基配列部分の触媒活性に
よる基質の切断に必要な様式で自己の内部に相補性結合を形成するDNA塩基配
列であればどのようなものでもよい。
本発明の触媒活性分子はApplied BiosystemsあるいはMil
ligenで製造されているような市販のDNA合成機により周知の方法で合成
される。例えば、前記ペローらの文献を参照せよ。
XおよびZの配列は細胞への侵入性、細胞内での標的指向性および触媒の最終的
安定性を高めるためにリガンドによってそれぞれの3°および5°の位置で置換
され得る。そのようなリガンドの非限定的な例示としては、他のヌクレオチド、
蛋白質、炭水化物、脂質、ステロイドホルモン、およびコレステロールが含まれ
る。
本発明の触媒活性分子はリポソーム、欠損ウィルス粒子、ウィルス頭部、および
標準的なりNA/RNA トランスフェクション法を含んだ、周知のおよび入手
可能な送達剤もしくは系により投与されるが、しかしこれらに限定されるもので
第1図はHIV−1の塩基配列と相補対を形成した本発明の触媒活性分子の一つ
を表す。分子のRNA部分は線で囲まれている。
第2図は他のHTV−1の塩基配列と相補的な配列をもつ本発明の触媒活性分子
の二つめを表す。分子のRNA部分は線で囲まれている。
第3図Aは同等の全DNA分子と比較して第1図の触媒活性分子のりポヌクレア
ーゼAによる消化を表す。条件は5hM Tris−BCI緩衝液(pH18,
0) 10μl中のオリゴヌクレオチドに2XSSC緩衝液中の市販されている
(Sigma)膵臓リボヌクレアーゼ10ユニツトを加えた。s2Pで末端ラベ
ルされたDRDRDあるいはDNA分子を8M尿素を含んだ15%ポリアクリル
アミドゲルで電気泳動する前にRNaseをサンプルと10分間インキュベート
した。ゲルを10分間オートラジオグラフ処理して、被照射部分を現像した。
第3図Bはチャン(Chang)ら、 C11nical Biotechno
logy4: 23−31 (1990)に述べられている条件で行われた第1
図の触媒活性分子を含む切断反応を表す。
実施例1
第1図の触媒活性分子はApplied Biosystems、 Incで製
造されている自動オリゴヌクレオチド合成機を利用して周知の方法により合成さ
れた。
触媒活性分子のりボヌクレアーゼAによる消化の結果は第3図Aに示されている
。
上記のようにして、生産された触媒活性分子は、それぞれ610ヌクレオチドい
られた。要約すると、緩衝液は標的分子およそ1 pmol、 DNAあるいは
りボザイム3 pmolにつき5hM Tris−BCl、 pH7,5,1m
M EDT^、 10mM MgChであった。反応は37℃において12時間
行われた。基質はHIV−1gag転写産物を含む610ヌクレオチド(S−6
10)とHIv−1jLAjL転写産物を含む172ヌクレオチド(S−172
)のいずれかである。両方のヌクレオチドともに5゜切断産物を示した。
第3図Bにおいて5゛切断産物は両方の転写産物について示されている。標的物
610の3°切断産物はオートラジオグラフィーにおける再現には量的に乏しい
ので見えない、しかし3’ Pの決定法によりその位置が示される。ネガティブ
コントロールとして、DRDRD配列と等しい塩基配列をもった全DNAオリゴ
ヌクレオチド(D)を同じ条件で同じ基質を用いてインキュベートしたが、切断
は起こらなかった。
同じ触媒活性分子をもちいたHIV−1の5’ LTRスプライス部位の特異的
な切断も起こすことができた。
Fg(:、 1DRDRD−1
蒼
FIG、 2 DRDRD i2
FIG、3A
DRD D
FIG、 3B
M DRD D
−−1−・
国際調査報告
Claims (7)
- 1.下記の式: 3′X−AAAG−Y−AGUAAGUC−Z5′あるいは 3′X−CAAAG−Y−AGUAAGUC−Z5′(式中、XおよびZはリボ ザイムの既知の切断部位と近接した位置において、RNA基質と相補対を形成し 得るDNA塩基配列部分であり、AAAG,CAAAGおよびAGUAGUCは RNA塩基配列部分を表し、Yは前記各RNA塩基配列部分が前記切断部位にお いて前記RNA基質を切断することを可能ならしめる様式で自己の内部で相補対 を形成し得るDNA塩基配列部分である。)で表される、リボザイム切断部位に おいてHIV−1のRNA塩基配列を切断することのできる触媒活性分子。
- 2.第1図に示された触媒活性分子。
- 3.第2図に示された触媒活性分子。
- 4.前記RNA塩基配列がHIV−1の塩基配列である、請求項1に記載の触媒 活性分子。
- 5.前記HIV−1塩基配列が第1図に示されたHIV−1の塩基配列である、 請求項4に記載の触媒活性分子。
- 6.HIV−1塩基配列が第2図に示されたHIV−1の塩基配列である、請求 項4に記載の触媒活性分子。
- 7.RNA基質の切断部位周辺の各RNA塩基配列と相補対を形成し得る第1お よび第2DNA部分に結合しておりさらに前記切断を促進するように自己の内部 で相補対を形成し得る第3のDNA塩基配列で相互に連結されているいくつかの 触媒活性RNA部分をもつ、RNA塩基配列を基質として切断することのできる 触媒活性分子。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40161389A | 1989-08-31 | 1989-08-31 | |
| US401,613 | 1989-08-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH04502256A true JPH04502256A (ja) | 1992-04-23 |
| JP3058686B2 JP3058686B2 (ja) | 2000-07-04 |
Family
ID=23588467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2508840A Expired - Fee Related JP3058686B2 (ja) | 1989-08-31 | 1990-06-05 | キメラdna―rna触媒活性配列 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0451221B1 (ja) |
| JP (1) | JP3058686B2 (ja) |
| AU (1) | AU637800B2 (ja) |
| CA (1) | CA2039718C (ja) |
| GB (1) | GB2242432B (ja) |
| WO (1) | WO1991003162A1 (ja) |
Families Citing this family (187)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4091533T (ja) * | 1989-08-31 | 1992-01-30 | ||
| US6365730B1 (en) * | 1990-06-19 | 2002-04-02 | Gene Shears Pty. Limited | DNA-Armed ribozymes and minizymes |
| ES2061416T3 (es) * | 1990-10-12 | 1997-03-01 | Max Planck Gesellschaft | Ribozimas modificadas. |
| US5652094A (en) * | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
| US6469158B1 (en) * | 1992-05-14 | 2002-10-22 | Ribozyme Pharmaceuticals, Incorporated | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| US5686599A (en) * | 1992-05-14 | 1997-11-11 | Ribozyme Pharmaceuticals, Inc. | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| US5693535A (en) * | 1992-05-14 | 1997-12-02 | Ribozyme Pharmaceuticals, Inc. | HIV targeted ribozymes |
| US5977343A (en) | 1992-05-14 | 1999-11-02 | Ribozyme Pharmaceuticals, Inc. | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| US5804683A (en) * | 1992-05-14 | 1998-09-08 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA with alkylamine |
| CA2114312A1 (en) * | 1992-05-27 | 1993-12-09 | John J. Rossi | Chimeric trnalys-ribozyme molecules |
| US5827935A (en) * | 1992-05-27 | 1998-10-27 | City Of Hope | Chimeric tRNAlys -ribozyme molecules |
| US5646042A (en) * | 1992-08-26 | 1997-07-08 | Ribozyme Pharmaceuticals, Inc. | C-myb targeted ribozymes |
| US5891684A (en) * | 1992-10-15 | 1999-04-06 | Ribozyme Pharmaceuticals, Inc. | Base-modified enzymatic nucleic acid |
| US5811300A (en) * | 1992-12-07 | 1998-09-22 | Ribozyme Pharmaceuticals, Inc. | TNF-α ribozymes |
| US5658780A (en) * | 1992-12-07 | 1997-08-19 | Ribozyme Pharmaceuticals, Inc. | Rel a targeted ribozymes |
| US5612215A (en) * | 1992-12-07 | 1997-03-18 | Ribozyme Pharmaceuticals, Inc. | Stromelysin targeted ribozymes |
| US5616488A (en) * | 1992-12-07 | 1997-04-01 | Ribozyme Pharmaceuticals, Inc. | IL-5 targeted ribozymes |
| US5837542A (en) | 1992-12-07 | 1998-11-17 | Ribozyme Pharmaceuticals, Inc. | Intercellular adhesion molecule-1 (ICAM-1) ribozymes |
| WO1995004818A1 (en) * | 1993-08-06 | 1995-02-16 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting human immunodeficiency virus replication |
| US5817635A (en) * | 1993-08-09 | 1998-10-06 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Modified ribozymes |
| ATE227342T1 (de) | 1993-09-02 | 2002-11-15 | Ribozyme Pharm Inc | Enzymatische nukleiksaüre die nicht-nukleotide enthaltet |
| ATE174600T1 (de) * | 1993-10-27 | 1999-01-15 | Ribozyme Pharm Inc | 2'-amido-und 2'-peptido-modifizierte oligonukleotide |
| CA2176035A1 (en) | 1993-11-08 | 1995-05-18 | Nassim Usman | Base-modified enzymatic nucleic acid |
| US5631359A (en) * | 1994-10-11 | 1997-05-20 | Ribozyme Pharmaceuticals, Inc. | Hairpin ribozymes |
| US5693532A (en) * | 1994-11-04 | 1997-12-02 | Ribozyme Pharmaceuticals, Inc. | Respiratory syncytial virus ribozymes |
| US6103890A (en) * | 1994-05-18 | 2000-08-15 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids that cleave C-fos |
| US5633133A (en) * | 1994-07-14 | 1997-05-27 | Long; David M. | Ligation with hammerhead ribozymes |
| US6468981B1 (en) * | 1994-07-29 | 2002-10-22 | Emory University | Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors |
| US5599706A (en) * | 1994-09-23 | 1997-02-04 | Stinchcomb; Dan T. | Ribozymes targeted to apo(a) mRNA |
| US5672501A (en) * | 1994-12-23 | 1997-09-30 | Ribozyme Pharmaceuticals, Inc. | Base-modified enzymatic nucleic acid |
| US5705388A (en) * | 1994-12-23 | 1998-01-06 | Ribozyme Pharmaceuticals, Inc. | CETP Ribozymes |
| US5663064A (en) * | 1995-01-13 | 1997-09-02 | University Of Vermont | Ribozymes with RNA protein binding site |
| US6004806A (en) * | 1995-06-07 | 1999-12-21 | Commonwealth Scientific And Industrial Research Organization | Optimized minizymes and miniribozymes and uses thereof |
| AU708995B2 (en) | 1995-06-07 | 1999-08-19 | Gene Shears Pty. Limited | Optimized minizymes and miniribozymes and uses thereof |
| US5877021A (en) * | 1995-07-07 | 1999-03-02 | Ribozyme Pharmaceuticals, Inc. | B7-1 targeted ribozymes |
| US6346398B1 (en) | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
| US7034009B2 (en) | 1995-10-26 | 2006-04-25 | Sirna Therapeutics, Inc. | Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) |
| US5807743A (en) * | 1996-12-03 | 1998-09-15 | Ribozyme Pharmaceuticals, Inc. | Interleukin-2 receptor gamma-chain ribozymes |
| US6057156A (en) | 1997-01-31 | 2000-05-02 | Robozyme Pharmaceuticals, Inc. | Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors |
| US6159951A (en) | 1997-02-13 | 2000-12-12 | Ribozyme Pharmaceuticals Inc. | 2'-O-amino-containing nucleoside analogs and polynucleotides |
| US6251666B1 (en) | 1997-03-31 | 2001-06-26 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid catalysts comprising L-nucleotide analogs |
| US6280936B1 (en) | 1997-06-09 | 2001-08-28 | Ribozyme Pharmaceuticals, Inc. | Method for screening nucleic acid catalysts |
| US6548657B1 (en) | 1997-06-09 | 2003-04-15 | Ribozyme Pharmaceuticals, Inc. | Method for screening nucleic acid catalysts |
| US6183959B1 (en) | 1997-07-03 | 2001-02-06 | Ribozyme Pharmaceuticals, Inc. | Method for target site selection and discovery |
| US6316612B1 (en) | 1997-08-22 | 2001-11-13 | Ribozyme Pharmaceuticals, Inc. | Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides |
| JP2001518292A (ja) * | 1997-09-22 | 2001-10-16 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | エンドヌクレアーゼ活性を有する核酸触媒 |
| US6656731B1 (en) | 1997-09-22 | 2003-12-02 | Max Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. | Nucleic acid catalysts with endonuclease activity |
| US6054576A (en) * | 1997-10-02 | 2000-04-25 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA |
| US6617438B1 (en) | 1997-11-05 | 2003-09-09 | Sirna Therapeutics, Inc. | Oligoribonucleotides with enzymatic activity |
| US6482932B1 (en) | 1997-11-05 | 2002-11-19 | Ribozyme Pharmaceuticals, Incorporated | Nucleoside triphosphates and their incorporation into oligonucleotides |
| US20020147143A1 (en) | 1998-03-18 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| EP1071753A2 (en) | 1998-04-20 | 2001-01-31 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
| US6995259B1 (en) | 1998-10-23 | 2006-02-07 | Sirna Therapeutics, Inc. | Method for the chemical synthesis of oligonucleotides |
| EP1183389A2 (en) | 1999-04-30 | 2002-03-06 | University of Florida | Adeno-associated virus-delivered ribozyme compositions and methods of use |
| US6379931B1 (en) * | 1999-08-12 | 2002-04-30 | City Of Hope | Chimeric DNA/RNA ribozymes containing propanediol |
| US6831171B2 (en) | 2000-02-08 | 2004-12-14 | Yale University | Nucleic acid catalysts with endonuclease activity |
| US8273866B2 (en) | 2002-02-20 | 2012-09-25 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA) |
| US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| AR029540A1 (es) | 2000-06-28 | 2003-07-02 | Corixa Corp | COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN |
| WO2002072790A2 (en) | 2001-03-14 | 2002-09-19 | Myriad Genetics, Inc | Tsg101-gag interaction and use thereof |
| EP1386004A4 (en) | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID |
| JP2005504513A (ja) | 2001-05-09 | 2005-02-17 | コリクサ コーポレイション | 前立腺癌の治療及び診断のための組成物及び方法 |
| US7517864B2 (en) | 2001-05-18 | 2009-04-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| EP2415486B1 (en) | 2001-05-18 | 2017-02-22 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
| US7205399B1 (en) | 2001-07-06 | 2007-04-17 | Sirna Therapeutics, Inc. | Methods and reagents for oligonucleotide synthesis |
| DK2224012T3 (da) | 2001-12-17 | 2013-05-13 | Corixa Corp | Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme |
| US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| EP1432724A4 (en) | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | RNA inhibition mediated inhibition of MAP KINASE GENES |
| US7655790B2 (en) | 2002-07-12 | 2010-02-02 | Sirna Therapeutics, Inc. | Deprotection and purification of oligonucleotides and their derivatives |
| US6989442B2 (en) | 2002-07-12 | 2006-01-24 | Sirna Therapeutics, Inc. | Deprotection and purification of oligonucleotides and their derivatives |
| US7923547B2 (en) | 2002-09-05 | 2011-04-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US20080260744A1 (en) | 2002-09-09 | 2008-10-23 | Omeros Corporation | G protein coupled receptors and uses thereof |
| EP3222294A1 (en) | 2003-04-30 | 2017-09-27 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US20060019914A1 (en) | 2004-02-11 | 2006-01-26 | University Of Tennessee Research Foundation | Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes |
| ES2423060T3 (es) | 2004-03-12 | 2013-09-17 | Alnylam Pharmaceuticals, Inc. | Agentes iRNA que tienen como diana al VEGF |
| US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
| WO2006020684A2 (en) | 2004-08-10 | 2006-02-23 | Institute For Multiple Myeloma And Bone Cancer Research | Methods of regulating differentiation and treating of multiple myeloma |
| PT1981902E (pt) | 2006-01-27 | 2015-11-02 | Biogen Ma Inc | Antagonistas dos recetores nogo |
| WO2007117657A2 (en) | 2006-04-07 | 2007-10-18 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
| CA2666657A1 (en) | 2006-10-18 | 2008-04-24 | Nastech Pharmaceutical Company Inc. | Nicked or gapped nucleic acid molecules and uses thereof |
| WO2008052774A2 (en) | 2006-10-31 | 2008-05-08 | Noxxon Pharma Ag | Methods for detection of a single- or double-stranded nucleic acid molecule |
| US20100129358A1 (en) | 2006-12-22 | 2010-05-27 | University Of Utah Research Foundation | Method of detecting ocular diseases and pathologic conditions and treatment of same |
| HUE040417T2 (hu) | 2007-05-04 | 2019-03-28 | Marina Biotech Inc | Aminosavlipidek és alkalmazásuk |
| WO2009073809A2 (en) | 2007-12-04 | 2009-06-11 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
| CA2721333C (en) | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
| WO2009155100A1 (en) | 2008-05-30 | 2009-12-23 | Yale University | Targeted oligonucleotide compositions for modifying gene expression |
| EP2323679A4 (en) | 2008-07-25 | 2012-08-22 | Univ Colorado | CLIP INHIBITORS AND METHODS FOR MODULATING IMMUNE FUNCTION |
| EP3025727A1 (en) | 2008-10-02 | 2016-06-01 | The J. David Gladstone Institutes | Methods of treating liver disease |
| CA2740000C (en) | 2008-10-09 | 2017-12-12 | Tekmira Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| JP2012505913A (ja) | 2008-10-16 | 2012-03-08 | マリーナ バイオテック,インコーポレイテッド | 遺伝子発現を抑制する治療におけるリポソームによる効率的な送達のプロセスおよび組成物 |
| EP2346904B1 (en) | 2008-10-29 | 2017-04-12 | China Synthetic Rubber Corporation | Methods and agents for the diagnosis and treatment of hepatocellular carcinoma |
| CN111808084A (zh) | 2008-11-10 | 2020-10-23 | 阿布特斯生物制药公司 | 用于递送治疗剂的新型脂质和组合物 |
| EP3243504A1 (en) | 2009-01-29 | 2017-11-15 | Arbutus Biopharma Corporation | Improved lipid formulation |
| CA2758189C (en) | 2009-04-10 | 2020-12-29 | Association Institut De Myologie | Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease |
| CN107252489A (zh) | 2009-04-13 | 2017-10-17 | 法国健康和医学研究院 | Hpv颗粒及其用途 |
| SG10201911942UA (en) | 2009-05-05 | 2020-02-27 | Muthiah Manoharan | Lipid compositions |
| CA3045126A1 (en) | 2009-05-05 | 2010-11-11 | Arbutus Biopharma Corporation | Methods of delivering oligonucleotides to immune cells |
| KR101766408B1 (ko) | 2009-06-10 | 2017-08-10 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| WO2011000107A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
| WO2011039646A2 (en) | 2009-09-30 | 2011-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Papilloma virus -like particles for targeted gene delivery |
| US8450090B2 (en) | 2009-10-06 | 2013-05-28 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for promoting fatty acid production in plants |
| EP3296398A1 (en) | 2009-12-07 | 2018-03-21 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
| EP3494963A1 (en) | 2009-12-18 | 2019-06-12 | The University of British Columbia | Methods and compositions for delivery of nucleic acids |
| EP2516681B1 (en) | 2010-02-11 | 2017-10-18 | Nanostring Technologies, Inc | Compositions and methods for the detection of preferably small rnas by bridge hybridisation and ligation |
| WO2011120023A1 (en) | 2010-03-26 | 2011-09-29 | Marina Biotech, Inc. | Nucleic acid compounds for inhibiting survivin gene expression uses thereof |
| WO2011133584A2 (en) | 2010-04-19 | 2011-10-27 | Marina Biotech, Inc. | Nucleic acid compounds for inhibiting hras gene expression and uses thereof |
| SG10201800541SA (en) | 2010-04-23 | 2018-03-28 | Univ Florida | Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1) |
| EP2563922A1 (en) | 2010-04-26 | 2013-03-06 | Marina Biotech, Inc. | Nucleic acid compounds with conformationally restricted monomers and uses thereof |
| WO2011139843A2 (en) | 2010-04-28 | 2011-11-10 | Marina Biotech, Inc. | Multi-sirna compositions for reducing gene expression |
| US10064885B2 (en) | 2010-07-09 | 2018-09-04 | Massachusetts Institute Of Technology | Metabolic gene, enzyme, and flux targets for cancer therapy |
| WO2012016188A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
| WO2012016184A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
| US9243246B2 (en) | 2010-08-24 | 2016-01-26 | Sirna Therapeutics, Inc. | Single-stranded RNAi agents containing an internal, non-nucleic acid spacer |
| WO2012044992A2 (en) | 2010-09-30 | 2012-04-05 | Agency For Science, Technology And Research (A*Star) | Methods and reagents for detection and treatment of esophageal metaplasia |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| WO2012068463A2 (en) | 2010-11-18 | 2012-05-24 | Beth Israel Deaconess Medicall Center, Inc. | Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt) |
| CA2824526C (en) | 2011-01-11 | 2020-07-07 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
| US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| EP2753631A1 (en) | 2011-09-07 | 2014-07-16 | Marina Biotech, Inc. | Synthesis and uses of nucleic acid compounds with conformationally restricted monomers |
| EP3456317B1 (en) | 2011-09-27 | 2025-09-24 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted pegylated lipids |
| BR112014008862A2 (pt) | 2011-10-14 | 2018-08-07 | Genentech Inc | anticorpo isolado que se liga à htra1, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, métodos e usos |
| JP2015502365A (ja) | 2011-12-12 | 2015-01-22 | オンコイミューニン,インコーポレイティド | オリゴヌクレオチドのイン−ビボ送達 |
| WO2013119877A1 (en) | 2012-02-07 | 2013-08-15 | Aura Biosciences, Inc. | Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells |
| EP2817287B1 (en) | 2012-02-24 | 2018-10-03 | Arbutus Biopharma Corporation | Trialkyl cationic lipids and methods of use thereof |
| WO2015006740A2 (en) | 2013-07-11 | 2015-01-15 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide-ligand conjugates and process for their preparation |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| EP3046583B1 (en) | 2013-09-18 | 2019-02-13 | Aura Biosciences, Inc. | Virus-like particle conjugates for treatment of tumors |
| WO2015048531A1 (en) | 2013-09-26 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Inhibition of sgk1 in the treatment of heart conditions |
| US10772974B2 (en) | 2013-11-18 | 2020-09-15 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for cardiac regeneration |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| WO2016061131A1 (en) | 2014-10-14 | 2016-04-21 | The J. David Gladstone Institutes | Compositions and methods for reactivating latent immunodeficiency virus |
| EP3331536A4 (en) | 2015-08-03 | 2019-03-27 | The Regents of The University of California | COMPOSITIONS AND METHODS OF MODULATING THE ABHD2 ACTIVITY |
| IL310721B2 (en) | 2015-10-23 | 2025-11-01 | Harvard College | Nucleobase editors and uses thereof |
| MY196448A (en) | 2015-10-30 | 2023-04-12 | Genentech Inc | Anti-Htra1 Antibodies and Methods of use Thereof |
| JP2018532801A (ja) | 2015-10-30 | 2018-11-08 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 標的化がん療法 |
| CN110214183A (zh) | 2016-08-03 | 2019-09-06 | 哈佛大学的校长及成员们 | 腺苷核碱基编辑器及其用途 |
| WO2018031683A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| US12390514B2 (en) | 2017-03-09 | 2025-08-19 | President And Fellows Of Harvard College | Cancer vaccine |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| IL269986B2 (en) | 2017-04-12 | 2024-06-01 | Aura Biosciences Inc | Targeted combination therapy |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| KR20250107288A (ko) | 2017-10-16 | 2025-07-11 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| WO2020191233A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| US20220204975A1 (en) | 2019-04-12 | 2022-06-30 | President And Fellows Of Harvard College | System for genome editing |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| CN114901253A (zh) | 2019-08-14 | 2022-08-12 | 爱康泰生治疗公司 | 用于递送核酸的改进的脂质纳米颗粒 |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| EP4058032A4 (en) | 2019-12-19 | 2024-01-10 | Entrada Therapeutics, Inc. | Compositions for delivery of antisense compounds |
| EP4121018A4 (en) | 2020-03-17 | 2024-07-03 | Genevant Sciences Gmbh | CATIONIC LIPIDS FOR LIPID DNANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLA CELLS |
| IL297761A (en) | 2020-05-08 | 2022-12-01 | Broad Inst Inc | Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence |
| AU2021403156A1 (en) | 2020-12-18 | 2023-07-13 | Genevant Sciences Gmbh | Peg lipids and lipid nanoparticles |
| EP4314016A1 (en) | 2021-03-31 | 2024-02-07 | Entrada Therapeutics, Inc. | Cyclic cell penetrating peptides |
| WO2022240760A2 (en) | 2021-05-10 | 2022-11-17 | Entrada Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR MODULATING mRNA SPLICING |
| EP4337263A1 (en) | 2021-05-10 | 2024-03-20 | Entrada Therapeutics, Inc. | Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity |
| AU2022271873A1 (en) | 2021-05-10 | 2024-01-04 | Entrada Therapeutics, Inc. | Compositions and methods for intracellular therapeutics |
| AU2022298774A1 (en) | 2021-06-23 | 2023-12-14 | Entrada Therapeutics, Inc. | Antisense compounds and methods for targeting cug repeats |
| US12465647B2 (en) | 2021-08-05 | 2025-11-11 | Sanegene Bio Usa Inc. | 1′-alkyl modified ribose derivatives and methods of use |
| EP4405368A1 (en) | 2021-09-22 | 2024-07-31 | Sanegene Bio USA Inc. | 2'-alkyl or 3'- alkyl modified ribose derivatives for use in the in-vivo delivery of oligonucleotides |
| EP4413015A1 (en) | 2021-10-05 | 2024-08-14 | Sanegene Bio USA Inc. | Polyhydroxylated cyclopentane derivatives and methods of use |
| CN118900701A (zh) | 2022-01-31 | 2024-11-05 | 盖纳万科学有限公司 | 聚(烷基噁唑啉)-脂质缀合物及含有聚(烷基噁唑啉)-脂质缀合物的脂质颗粒 |
| KR20240146674A (ko) | 2022-01-31 | 2024-10-08 | 제네반트 사이언시즈 게엠베하 | 지질 나노입자를 위한 이온화 가능한 양이온성 지질 |
| US20230346819A1 (en) | 2022-02-22 | 2023-11-02 | Sanegene Bio Usa Inc. | 5'-modified carbocyclic ribonucleotide derivatives and methods of use |
| EP4555088A1 (en) | 2022-07-11 | 2025-05-21 | Sanegene Bio USA Inc. | Optimized 2'- modified ribose derivatives and methods of use |
| MX2025013094A (es) | 2023-05-03 | 2026-02-03 | Sanegene Bio Usa Inc | Conjugados basados en lipidos para la administracion sistemica en el sistema nervioso central, el sistema nervioso periferico y ocular |
| US20250064939A1 (en) | 2023-07-24 | 2025-02-27 | Sanegene Bio Usa Inc. | Lipid-based enhancement agent for rna delivery and therapy |
| WO2025052278A1 (en) | 2023-09-05 | 2025-03-13 | Genevant Sciences Gmbh | Pyrrolidine based cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells |
| WO2025133951A1 (en) | 2023-12-21 | 2025-06-26 | Genevant Sciences Gmbh | Ionizable lipids suitable for lipid nanoparticles |
-
1990
- 1990-06-05 AU AU58177/90A patent/AU637800B2/en not_active Ceased
- 1990-06-05 EP EP90909257A patent/EP0451221B1/en not_active Expired - Lifetime
- 1990-06-05 WO PCT/US1990/003102 patent/WO1991003162A1/en not_active Ceased
- 1990-06-05 CA CA002039718A patent/CA2039718C/en not_active Expired - Fee Related
- 1990-06-05 JP JP2508840A patent/JP3058686B2/ja not_active Expired - Fee Related
-
1991
- 1991-04-29 GB GB9109228A patent/GB2242432B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO1991003162A1 (en) | 1991-03-21 |
| GB2242432B (en) | 1993-07-07 |
| AU637800B2 (en) | 1993-06-10 |
| EP0451221B1 (en) | 1994-10-12 |
| AU5817790A (en) | 1991-04-08 |
| EP0451221A4 (en) | 1991-12-11 |
| EP0451221A1 (en) | 1991-10-16 |
| JP3058686B2 (ja) | 2000-07-04 |
| CA2039718A1 (en) | 1991-03-01 |
| CA2039718C (en) | 2003-02-25 |
| GB2242432A (en) | 1991-10-02 |
| GB9109228D0 (en) | 1991-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH04502256A (ja) | キメラdna―rna触媒活性配列 | |
| US5149796A (en) | Chimeric DNA-RNA catalytic sequences | |
| Knapp et al. | Splicing of yeast tRNA precursors: structure of the reaction intermediates | |
| Bartel et al. | Isolation of new ribozymes from a large pool of random sequences | |
| JP3015463B2 (ja) | 真核リボヌクレアーゼpを用いるrnaの標的化切断および外部ガイド配列 | |
| Jenkins et al. | Critical contacts between HIV‐1 integrase and viral DNA identified by structure‐based analysis and photo‐crosslinking | |
| US5910408A (en) | Catalytic DNA having ligase activity | |
| AU680405B2 (en) | Nucleozymes | |
| Saxena et al. | Ribozymes correctly cleave a model substrate and endogenous RNA in vivo. | |
| Goodchild | Enhancement of ribozyme catalytic activity by a contiguous oligodeoxynucleotide (facilitator) and by 2′-O-methylation | |
| Fedor | Tertiary structure stabilization promotes hairpin ribozyme ligation | |
| Heidenreich et al. | RNase H-independent antisense activity of oligonucleotide N3′→ P5′ phosphoramidates | |
| JPH07502898A (ja) | 酵素rna分子 | |
| Downs et al. | Kinetic pathway for folding of the Tetrahymena ribozyme revealed by three UV-inducible crosslinks. | |
| DE3855864D1 (de) | Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene | |
| WO2000024931A2 (en) | Detection of analytes | |
| Earnshaw et al. | Modified oligoribonucleotides as site‐specific probes of RNA structure and function | |
| Benseler et al. | Hammerhead-like molecules containing non-nucleoside linkers are active RNA catalysts | |
| CA2400415A1 (en) | Nucleic acid sensor molecules | |
| Nashimoto | Conversion of mammalian tRNA 3′ processing endoriubonuclease to four-base-recognizing RNA cutters | |
| Nashimoto | Specific cleavage of target RNAs from HIV-1 with 5'half tRNA by mammalian tRNA 3'processing endoribonuclease | |
| Taira et al. | Construction of a novel artificial-ribozyme-releasing plasmid | |
| Jabri et al. | Kinetic and secondary structure analysis of Naegleria andersoni GIR1, a group I ribozyme whose putative biological function is site-specific hydrolysis | |
| Jayasena et al. | In vitro selection of RNA specifically cleaved by bacteriophage T4 RegB endonuclease | |
| KR950704495A (ko) | 카바모일 포스페이트 합성효소ⅱ의 유전정보를 보유하고 있는 뉴클레오티드 배열[nucleotide sequence encoding carbamoyl phosphate synthetase ⅱ] |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |